FIELD: medicine, pharmaceutics.
SUBSTANCE: perorally delivered pharmaceutical composition contains a compound, which inhibits a protein of family Bcl-2, in particular ABT-263, a slightly soluble in lipids antioxidant, selected from the group, which consists of sulphites, bisulphites, metabisulphites, thiosulphates and their mixtures, and an in fact non-aqueous lipid carrier, which includes a phospholipid, a non-phospholipid surface-active substance and a solubilising component, which includes one or more glycols, glycolides and/or glyceride compounds, where the said compound ABT-263 and the said antioxidant are in a solution in the lipid carrier.
EFFECT: composition is suitable for peroral introduction to an individual who requires it for treatment of a disease, characterised by superexpression of one or some antiapoptotic proteins of family Bcl-2, for example cancer.
28 cl, 2 dwg, 17 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ABT-263 CAPSULE | 2010 |
|
RU2550956C2 |
| ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR TREATMENT OF BCL-2 PROTEIN RELATED DISEASES | 2010 |
|
RU2551376C2 |
| PHARMACEUTICAL DOSED FORM FOR PERORAL INTRODUCTION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2568599C2 |
| PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2711359C2 |
| SOLID DISPERSIONS CONTAINING APOPTOSIS PROMOTING PROTEINS | 2010 |
|
RU2550134C2 |
| SALTS AND CRYSTALLINE FORMS OF APOTTOSIS-INDUCING AGENT | 2011 |
|
RU2628560C2 |
| COMBINED THERAPY WITH TYPE II ANTI-CD20 ANTIBODIES IN COMBINATION WITH ANTI-BCL-2 ACTIVE AGENT | 2008 |
|
RU2541805C2 |
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
| SEMIFIRM SYSTEMS CONTAINING DERIVATIVES OF AZETIDINUM | 2004 |
|
RU2343915C2 |
| COMPOUNDS AND METHODS FOR INHIBITING Bcl PROTEIN INTERACTION WITH BINDING PARTNERS | 2007 |
|
RU2449996C2 |
